Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment for advanced esophageal squamous cell carcinoma
2018-000587-28Phase 3Completed
- Sponsor
- BeiGene
- Start
- Dec 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Esophageal Squamous Cell Carcinoma (ESCC) comparing Tislelizumab plus chemotherapy with Placebo plus chemotherapy (2 arms). Primary endpoint: Overall survival. Started Dec 2018; status: completed.
02
Drugs
tislelizumab
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on 2018-000587-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-000587-28.